Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814462 | 1.00 | DPP4 (0.68) | DPP4CYP3A4CHRM1 | |
| SCHEMBL4810473 | 0.96 | DPP4 (0.72) | DPP4CYP3A4CHRM1 | |
| SCHEMBL4810486 | 0.96 | DPP4 (0.72) | DPP4CYP3A4CHRM1 | |
| SCHEMBL4816818 | 0.93 | DPP4 (0.67) | DPP4CYP3A4CHRM1 | |
| SCHEMBL4816807 | 0.93 | DPP4 (0.67) | DPP4CYP3A4CHRM1 | |
| SCHEMBL8283517 | 0.90 | DPP4 (0.56) | DPP4CYP3A4 | |
| SCHEMBL14045480 | 0.90 | DPP4 (0.56) | DPP4CYP3A4 | |
| SCHEMBL4811036 | 0.90 | DPP4 (0.70) | DPP4CYP3A4CHRM1 | |
| SCHEMBL4811043 | 0.90 | DPP4 (0.70) | DPP4CYP3A4CHRM1 | |
| SCHEMBL4805614 | 0.90 | DPP4 (0.70) | DPP4CYP3A4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432262-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-07 | — | — | US | disclosed |
| US-7432262-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-07 | — | — | US | disclosed |
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | ECKHARDT MATTHIAS | 2007-06-21 | — | — | US | disclosed |
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | ECKHARDT MATTHIAS | 2007-06-21 | — | — | US | disclosed |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 13/4885CHRM1 624/4885 |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 13/4885CHRM1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.